RHOA and melanoma: In summary, using a drug repurposing screening approach, we have identified acquired pharmacological vulnerabilities to compounds that result in mitotic disruption in three different poorly differentiated BRAFi resistant human melanoma cell lines which also exhibit enhanced RhoA/C signaling (23).